Portal de investigación
Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists.
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Grupos y Plataformas de I+D+i
Abstract
The increasing prevalence of obesity and type 2 diabetes (T2DM) is provoking an important socioeconomic burden mainly in the form of cardiovascular disease (CVD). One successful strategy is the so-called metabolic surgery whose beneficial effects are beyond dietary restrictions and weight loss. One key underlying mechanism behind this surgery is the cooperative improved action of the preproglucagon-derived hormones, glucagon, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) which exert their functions through G protein-coupled receptors (GPCR). Great success has been reached with therapies based on the GLP-1 receptor monoagonism; therefore, a logical and rational approach is the use of the dual and triagonism of GCPC to achieve complete metabolic homeostasis. The present review describes novel findings regarding the complex biology of the preproglucagon-derived hormones, their signaling, and the drug development of their analogues, especially those acting as dual and triagonists. Moreover, the main investigations into animal models and ongoing clinical trials using these unimolecular dual and triagonists are included which have demonstrated their safety, efficacy, and beneficial effects on the CV system. These therapeutic strategies could greatly impact the treatment of CVD with unprecedented benefits which will be revealed in the next years.
Datos de la publicación
- ISSN/ISSNe:
- 2072-6643, 2072-6643
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.3390/nu14183775
- PubMed:
- 36145148
Nutrients MDPI AG
Citas Recibidas en Web of Science: 2
Documentos
Filiaciones
Keywords
- GPCR agonism; cardiometabolism; clinical trial; glucagon; incretins; type 2 diabetes mellitus
Financiación
Proyectos y Estudios Clínicos
Role of the inflammatory processes in metabolic diseases and associated complications. Papel de los procesos inflamatorios en las enfermedades metabólicas y sus complicaciones asociadas.
Investigador Principal: HERMINIA GONZÁLEZ NAVARRO
PI19/00169 . INSTITUTO SALUD CARLOS III . 2020
CONTRATOS PREDOCTORALES DE FORMACIÓN EN INVESTIGACIÓN EN SALUD.
Investigador Principal: MARÍA AGUILAR BALLESTER
FI20/00017 . INSTITUTO SALUD CARLOS III; MINISTERIO ECONOMIA Y COMPETITIVIDAD . 2021
Papel de la vía de señalización mediada por LIGHT en la reprogramación de las células de músculo liso vascular en la aterosclerosis.
Investigador Principal: GEMA HURTADO GENOVÉS
FPU20/04916 . MINISTERIO EDUCACION, CULTURA Y DEPORTE . 2021
Cita
Jimenez E,Hurtado G,Aguilar M,Martinez S,Gonzalez H. Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists. Nutrients. 2022. 14. (18):3775. IF:5,900. (1).
Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists. Jimenez E, Hurtado G, Aguilar M, Martinez S, Gonzalez H. Nutrients. 2022 septiembre 13. 14 (18):DOI:10.3390/nu14183775. PMID:36145148.
